Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab and Etoposide in HER2+ Metastatic Breast Cancer
NCT00810017Phase 2Terminated
- Sponsor
- MedStar Health Research Institute
- Start
- Feb 2009
- Primary completion
- May 2010
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label trial of etoposide and trastuzumab in HER2-positive metastatic breast cancer, sponsored by MedStar Health Research Institute. Primary endpoints: Objective Response Rate at 24 months and Toxicity at 24 months. Started Feb 2009; status: terminated.
02
Drugs
etoposidetrastuzumab
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT00810017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00810017.